Atlas Trials

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Clinical trial NCT02987829 · COMPLETED

Trial details

NCT number
NCT02987829
Sponsor
Tracon Pharmaceuticals Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Castrate-resistant Prostate CancerAdenocarcinoma, Prostate
Start date
2017-05-23
Primary completion
2019-10-06
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.